Tonny
Thursday is here and guess what?
Catalyst Pharmaceuticals, Inc.
CPRX put it on your Radar!
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), infantile spasms, and Tourette's Disorder. Catalyst's lead candidate, Firdapse® for the treatment of LEMS, has completed testing in a global, multi-center, double-blinded randomized pivotal Phase 3 trial resulting in positive top-line data and Catalyst has recently filed an NDA for this product seeking approval for its use as a treatment of LEMS and CMS. Firdapse for the treatment of LEMS has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) and orphan drug designation for LEMS and CMS. Firdapse is the first and only European approved drug for symptomatic treatment in adults with LEMS.
Catalyst is also developing CPP-115 to treat infantile spasms, epilepsy and other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder and Tourette's Disorder. CPP-115 has been granted U.S. orphan drug designation for the treatment of infantile spasms by the FDA and has been granted E.U. orphan medicinal product designation for the treatment of West Syndrome by the European Commission. In addition, Catalyst is developing a generic version of Sabril® (vigabatrin).
Headlines
- Catalyst Pharmaceuticals (CPRX) Stock Plunges After FDA 'Refusal to File' Letterat TheStreet(Wed, Feb 17)
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Catalyst Pharmaceuticals, Inc.Business Wire(Wed, Feb 17)
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Pharmaceuticals, Inc. - CPRXAccesswire(Wed, Feb 17)
- SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Catalyst Pharmaceuticals, Inc. (CPRX)PR Newswire(Wed, Feb 17)
- Catalyst Pharmaceuticals Crashes 50% Following 'Refusal To File' Letter From FDABenzinga(Wed, Feb 17)
- Catalyst Pharma Plummets on FDA 'Refuse-to-File' Letterat TheStreet(Wed, Feb 17)
- CATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Wed, Feb 17)
- 6:51 am Catalyst Pharma receives a 'Refusal to File' letter from the FDA regarding its NDA for Firdapse; plans to request meeting w/ FDA to discussBriefing.com(Wed, Feb 17)
- Catalyst Pharmaceuticals Receives "Refusal to File" Letter From the FDA on Its NDA for FirdapseGlobeNewswire(Wed, Feb 17)
- Catalyst (CPRX) Initiates Study on Firdapse for MuSK-MGZacks(Tue, Feb 9)
- CATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Mon, Feb 8)
- Catalyst Pharmaceuticals Announces Initiation of Investigator-Sponsored Study of Firdapse in Patients With MuSK-Antibody Positive Myasthenia GravisGlobeNewswire(Mon, Feb 8)
Never invest in a stock mentioned by StockPalooza.com.com unless you can afford to lose your entire investment.
Release of Liability: Through use of this website viewing or using you agree to holdStockPalooza.com.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may suffer. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Please be advised that StockPalooza.com.com is often compensated for issuing press releases, profiles or opinions concerning particular companies, its opinion is therefore biased and you should consider the factor when evaluating StockPalooza.com.com's statements regarding a company. StockPalooza.com.com's officers and directors do not own any shares of the mentioned company(s). When StockPalooza.com.com receives free or restric ted trading shares as a compensation for a profiled company, StockPalooza.com .com may sell part or all of such shares during the period in which StockPalooza.com.com is performing such services. StockPalooza.com.com will disclose how many and what type of shares we have been compensated if we do receive shares or buy shares of a profiled company.StockPalooza.com.com has been compensated zero Cash via Bank Wire Transfer by a third party for a 1 day Marketing Program regarding CPRX. This compensation/expected compensation, expired or not, is a major conflict of interest in our ability to be unbiased. Therefore, this newsletter should be read as a commercial advertisement only. The third party, company, or their affiliates may wish to liquidate shares, which has the potential to hurt share prices . Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the t imeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. StockPalooza.com.comencourages readers and investors to supplement the information in this report with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockPalooza.com.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. StockPalooza.com.com, nor any of its affiliates are not registered investment. Stockpalooza's emails and alerts are intended for novelty purposes only.
11020 Vanowen St No. Hollywood CA 91605
|
|
|
|
